Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.

Mol Oncol · 2021 · PMC8410523 · PMID 33934494

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

(2015) showed a trend toward a better survival for patients treated with regorafenib who presented KRAS or PIK3CA WT genotypes, assessed using tissue DNA or circulating cell‐free DNA (cfDNA).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.